RAD51 recombinase gene promoter (RAD51 promoter)

The RAD51 recombinase gene promoter is a critical regulatory DNA sequence located upstream of the RAD51 coding region that governs the transcriptional activity of the RAD51 protein, the central enzyme in the homologous recombination (HR) pathway for repairing double-strand DNA breaks (PMID: 12084574). In many aggressive malignancies, including breast, ovarian, and pancreatic cancers, this promoter is frequently overactive or overexpressed, leading to high levels of RAD51 that facilitate the repair of therapy-induced DNA damage and contribute to significant chemoresistance and radioresistance (PMID: 15173161). Therapeutic strategies targeting the RAD51 promoter DNA directly involve the use of experimental agents such as triplex-forming oligonucleotides (TFOs) or G-quadruplex-stabilizing ligands that bind specifically to the promoter sequence to physically obstruct transcription (PMID: 22373145). By suppressing RAD51 expression at the source, these interventions aim to induce a state of temporary DNA repair deficiency, thereby sensitizing tumor cells to DNA-damaging agents like cisplatin or ionizing radiation. While primarily a research and preclinical target, the RAD51 promoter represents a novel approach in precision oncology to overcome the survival advantages of DNA-repair-proficient cancer cells.

Other names

RAD51 regulatory regionRAD51 promoter DNARAD51 gene regulatory element

The primary mechanism involves the sequence-specific binding of therapeutic agents, such as triplex-forming oligonucleotides (TFOs) or G-quadruplex ligands, to the RAD51 promoter DNA. This binding physically obstructs the recruitment of RNA polymerase II and essential transcription factors like Sp1 and E2F1, thereby suppressing the transcription of the RAD51 gene (PMID: 15173161, PMID: 22373145). Consequently, the reduction in RAD51 mRNA and protein levels impairs the cell's homologous recombination repair capacity, sensitizing it to DNA-damaging agents.